Complementary function of the two catalytic domains of APOBEC3G
- PMID: 15721369
- DOI: 10.1016/j.virol.2005.01.011
Complementary function of the two catalytic domains of APOBEC3G
Abstract
The HIV-1 viral accessory protein Vif prevents the encapsidation of the antiviral cellular cytidine deaminases APOBEC3F and APOBEC3G by inducing their proteasomal degradation. In the absence of Vif, APOBEC3G is encapsidated and blocks virus replication by deaminating cytosines of the viral cDNA. APOBEC3G encapsidation has been recently shown to depend on the viral nucleocapsid protein; however, the role of RNA remains unclear. Using APOBEC3G deletion and point mutants, we mapped the encapsidation determinant to the Zn(2+) coordination residues of the N-terminal catalytic domain (CD1). Notably, these residues were also required for RNA binding. Mutations in the two aromatic residues of CD1 but not CD2, which are conserved in cytidine deaminase core domains and are required for RNA binding, prevented encapsidation into HIV-1, HTLV-I and MLV. The Zn(2+) coordination residues of the C-terminal catalytic domain (CD2) were not required for encapsidation but were essential for cytidine deaminase activity and the antiviral effect. These findings suggest a model in which CD1 mediates encapsidation and RNA binding while CD2 mediates cytidine deaminase activity. Interestingly, HTLV-I was relatively resistant to the antiviral effects of encapsidated APOBEC3G.
Similar articles
-
Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif.Cell. 2003 Jul 11;114(1):21-31. doi: 10.1016/s0092-8674(03)00515-4. Cell. 2003. PMID: 12859895
-
New insights into the role of Vif in HIV-1 replication.AIDS Rev. 2004 Jan-Mar;6(1):34-9. AIDS Rev. 2004. PMID: 15168739 Review.
-
APOBEC3G targets human T-cell leukemia virus type 1.Retrovirology. 2005 May 19;2:32. doi: 10.1186/1742-4690-2-32. Retrovirology. 2005. PMID: 15943885 Free PMC article.
-
Functional analysis of the two cytidine deaminase domains in APOBEC3G.Virology. 2011 Jun 5;414(2):130-6. doi: 10.1016/j.virol.2011.03.014. Epub 2011 Apr 13. Virology. 2011. PMID: 21489586
-
HIV-1 Vif: HIV's weapon against the cellular defense factor APOBEC3G.Curr HIV Res. 2005 Oct;3(4):339-44. doi: 10.2174/157016205774370456. Curr HIV Res. 2005. PMID: 16250885 Review.
Cited by
-
Emerging complexities of APOBEC3G action on immunity and viral fitness during HIV infection and treatment.Retrovirology. 2012 Apr 30;9:35. doi: 10.1186/1742-4690-9-35. Retrovirology. 2012. PMID: 22546055 Free PMC article. Review.
-
APOBEC family proteins: novel antiviral innate immunity.Int J Hematol. 2006 Apr;83(3):213-6. doi: 10.1532/IJH97.05187. Int J Hematol. 2006. PMID: 16720550 Review.
-
Restriction factors in human retrovirus infections and the unprecedented case of CIITA as link of intrinsic and adaptive immunity against HTLV-1.Retrovirology. 2019 Nov 29;16(1):34. doi: 10.1186/s12977-019-0498-6. Retrovirology. 2019. PMID: 31783769 Free PMC article. Review.
-
Structural basis of antagonism of human APOBEC3F by HIV-1 Vif.Nat Struct Mol Biol. 2019 Dec;26(12):1176-1183. doi: 10.1038/s41594-019-0343-6. Epub 2019 Dec 2. Nat Struct Mol Biol. 2019. PMID: 31792451 Free PMC article.
-
Different mutagenic potential of HIV-1 restriction factors APOBEC3G and APOBEC3F is determined by distinct single-stranded DNA scanning mechanisms.PLoS Pathog. 2014 Mar 20;10(3):e1004024. doi: 10.1371/journal.ppat.1004024. eCollection 2014 Mar. PLoS Pathog. 2014. PMID: 24651717 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources